ADAR1 Capital Management’s CG Oncology CGON Stock Holding History

ADAR1 Capital Management’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.43M	Sell	118,664 -67,035	-36%	-$4.38M	0.39%	62
2026 Q1	$12.6M	Sell	185,699 -72,440	-28%	-$4.1M	0.74%	34
2025 Q4	$10.7M	Buy	258,139 +9,222	+4%	+$382K	0.79%	33
2025 Q3	$10M	Sell	248,917 -274,299	-52%	-$7.97M	0.94%	25
2025 Q2	$13.6M	Buy	523,216 +222,082	+74%	+$5.35M	2.09%	11
2025 Q1	$7.37M	Buy	301,134 +85,384	+40%	+$2.4M	1.37%	17
2024 Q4	$6.19M	Buy	215,750 +72,646	+51%	+$2.49M	1.24%	17
2024 Q3	$5.4M	Buy	143,104 +130,254	+1,014%	+$4.57M	0.88%	27
2024 Q2	$406K	Buy	12,850 +10,800	+527%	+$374K	0.08%	109
2024 Q1	$90K	Buy	+2,050	New	+$83.7K	0.02%	156

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ADAR1 Capital Management's CGON Position: Q2 2026 in Review

ADAR1 Capital Management reduced its CG Oncology (CGON) stake by 36% in Q2 2026, selling an estimated $4.38M and leaving 118,664 shares worth $8.43M. The position accounts for 0.39% of the portfolio, ranked #62.

ADAR1 Capital Management first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. The position peaked at $13.6M in Q2 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

ADAR1 Capital Management held 118,664 shares of CG Oncology worth $8.43M as of Q2 2026.
ADAR1 Capital Management sold 67,035 CG Oncology shares in Q2 2026, an estimated $4.38M.
CG Oncology made up 0.39% of ADAR1 Capital Management's portfolio in Q2 2026, its #62 holding.
ADAR1 Capital Management first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
ADAR1 Capital Management's CG Oncology position peaked at $13.6M in Q2 2025.
227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.